Kliton Jorgo, Polgár Csaba, Tenke Péter, Kovács Gábor, Major Tibor, Stelczer Gábor, Ágoston Péter
Sugárterápiás Központ, Országos Onkológiai Intézet Budapest, Ráth Gy. u. 7-9., 1122.
Onkológiai Tanszék, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest.
Orv Hetil. 2017 Dec;158(51):2041-2047. doi: 10.1556/650.2017.30904.
To implement lipiodol as a fiducial marker of the tumor bed for image-guided radiotherapy with simultaneous integrated boost technique as part of radiochemotherapy for muscle invasive bladder tumors.
Since April 2016, radiochemotherapy was performed in 3 male patients with muscle invasive, transitional cell bladder carcinoma. Prior to radiochemotherapy, tumor bed resection was performed for each patient, at the same time 10 ml of lipiodol solution was injected submucosally into the resection site, thus marking the tumor bed for escalated dose irradiation. During radiochemotherapy 51 Gy (1.7 Gy/die) to the pelvis, 57 Gy (1.9 Gy/die) to the whole bladder, and 63 Gy (2.1 Gy/die) to the lipiodol-labeled tumor bed was delivered with simultaneous integrated boost technique. The accuracy of the irradiation was controlled by daily kilovoltage CT. Early radiogenic urogenital and gastrointestinal side effects were recorded according to Radiation Therapy Oncology Group side-effects grading recommendation.
Substantial perioperative side effect or toxicity were not observed during and after the injection of lipiodol. The prescribed dose was successfully delivered in all patients. Radiotherapy duration was 6 weeks. The lipiodol-labeled tumor bed was clearly visible on daily kilovoltage cone beam CT. In one patient grade II cystitis and proctitis was observed, another patient experienced only grade I cystitis. These complaints improved with symptomatic medication. In the third patient no significant side effect occurred.
The injection of lipiodol into the bladder wall is a safe technique, without any perioperative toxicity or complication. The tumor bed demarcated by lipiodol was visible both on treatment planning and kilovoltage CTs. The total treatment time was shortened by 4 days. The treatment was well tolerated, early side effects were moderate, or slight. Orv Hetil. 2017; 158(51): 2041-2047.
将碘油用作肿瘤床的基准标记物,用于图像引导放射治疗,并采用同步整合加量技术,作为肌肉浸润性膀胱肿瘤放化疗的一部分。
自2016年4月起,对3例男性肌肉浸润性移行细胞膀胱癌患者进行了放化疗。在放化疗前,对每位患者进行肿瘤床切除术,同时将10毫升碘油溶液黏膜下注射到切除部位,从而标记肿瘤床以进行剂量递增照射。在放化疗期间,采用同步整合加量技术,对盆腔给予51 Gy(1.7 Gy/次)、对整个膀胱给予57 Gy(1.9 Gy/次)、对碘油标记的肿瘤床给予63 Gy(2.1 Gy/次)的照射。通过每日千伏CT控制照射的准确性。根据放射肿瘤学组的副作用分级建议记录早期放射性泌尿生殖系统和胃肠道副作用。
在注射碘油期间及之后未观察到严重的围手术期副作用或毒性。所有患者均成功给予了规定剂量。放疗持续时间为6周。在每日千伏锥形束CT上,碘油标记的肿瘤床清晰可见。1例患者出现II级膀胱炎和直肠炎,另1例患者仅经历I级膀胱炎。这些症状经对症药物治疗后有所改善。第3例患者未出现明显副作用。
向膀胱壁注射碘油是一种安全的技术,无任何围手术期毒性或并发症。在治疗计划和千伏CT上均可看到由碘油划定的肿瘤床。总治疗时间缩短了4天。治疗耐受性良好,早期副作用为中度或轻度。《匈牙利医学周报》。2017年;158(51): 2041 - 2047。